Open AccessAcute Endothelin A Receptor Blockade in Heart Failure
Author(s) -
Alison Seed,
John J.V. McMurray
Publication year - 2001
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/01.cir.103.18.e94
Subject(s) - medicine , heart failure , vascular resistance , endothelin receptor , placebo , hemodynamics , blockade , pulmonary artery , blood pressure , pulmonary hypertension , cardiology , receptor , pathology , alternative medicine
To the Editor: We were surprised by the findings of Givertz et al and their interpretation.1 These authors describe the acute (6-hour) hemodynamic effects of 3 doses of the intravenous endothelin (ET) A receptor-selective antagonist sitaxsentan, compared with placebo, in patients with severe chronic heart failure. The patients studied had a strikingly high pulmonary vascular resistance (PVR) and mean pulmonary artery pressure compared with those in similar studies of other ET-1 receptor antagonists.2 3 4 5 Sixteen patients received placebo, 8 received sitaxsentan 1.5 mg/kg, 16 received sitaxsentan 3.0 mg/kg, and 8 received sitaxsentan …
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom